https://www.nejm.org/doi/full/10.1056/NEJMoa2304594
0
0
Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC | NEJM - nejm.org
6/4/23 at 7:00pm
Organization
nejm.org
Author
nejm.org
Details
12 words
Summarize
Create an account or login to join the discussion